It takes, on average, somewhere around 15 years and a billion dollars to take a drug development project “from bench to bedside.” One factor contributing greatly to that protracted timeline is the significant difficulty in finding and then collaborating with qualified partners. The problem is exacerbated when development is taking place on a global scale. Asking colleagues and consultants might net you a recommendation for the largest CROs, but if you need a good regulatory consultant familiar with Chinese Investigator Document Review, for example, you could be out of luck. And even when a pharma company does identify a service provider, the interaction isn't straightforward: there is no simple way of searching for and comparing services, profiles and reputation.

There are myriad websites designed to help consumers find hotels and local businesses, and they have made these transactions much more transparent. However, the life sciences industry has lagged behind: companies still mainly generate leads on development partners largely by word of mouth and by attending industry trade shows and conferences. In this audio conference, our speaker explores new ways to connect, evaluate and engage drug development partners around the world.

This audio conference covers:

• Why the current drug discovery & development model is unsustainable
• How big pharma is seeking greater flexibility in sharing risks for developing promising molecules
• The trend toward pharmaceutical discovery and development outsourcing to help offset risks
• Why outsourcing is posed for enormous growth in emerging regions, especially Eastern Europe, India, China and Latin America
• Insights into using online tools to research and evaluate drug development partners

About the speaker:

Jae Chung is the founder and CEO of goBalto.com – an online collaboration platform for the drug discovery and development industry. Prior to goBalto, Jae co-founded Celltrion, the 3rd largest contract biopharmaceutical group in the world, valued at over $1.6 billion. As Celltrion’s vice president of business development, he secured deals with Bristol-Myers Squibb and CSL, and has been credited with landing the largest biomanufacturing supply agreement in Asia to date. Before starting Celltrion in 2002, Mr. Chung was the co-founder of the venture capital firm J. Stephen & Company Ventures, a strategy consultant at McKinsey and Company. He holds a B.S. in accounting and M.B.A. in finance and economics from the NYU Stern School of Business.

Who should attend?

• Research Scientists
• VP or Manager Clinical Research
• VP or Manager Manufacturing, Quality, Regulatory
• VP or Manager of Procurement and Sourcing
• Business Development